Ferritin Assay
Ferritin Assay
Reagent | Ferritin
The Most Sensitive and Specific Diagnostic Test for Iron Deficiency
Benefits of Ferritin
Exceptional correlation
A correlation coefficient of r=0.99 was displayed when the Randox ferritin assay was compared to commercially available methods.
Limited interference
The Randox ferritin assay has shown to have limited interference from bilirubin, haemoglobin and triglycerides.
Applications available
Applications available detailing instrument-specific settings for the convenient use of the Randox ferritin assay on a variety of clinical chemistry analysers.
Excellent stability
The Randox ferritin assay is stable to expiry when stored at +2oC to +8oC.
Calibrator and controls available
Calibrator and controls available offering a complete testing package.
Ordering Information
| Cat No | Size | ||||
|---|---|---|---|---|---|
| FN3452 | R1 1 x 40ml (L) R2 1 x 20ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| FN3888 | R1 3 x 20ml (L) R2 3 x 11ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| FN8037 | R1 4 x 16.2ml R2 4 x 10.2ml | Enquire | Kit Insert Request | MSDS | Buy Online |
| (L) Indicates liquid option | |||||
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Diagnostic Uses
Ferritin is an iron storage protein. It is the primary iron storage mechanism and is critical to iron homeostasis. As an iron store, ferritin has two roles 1.
- Provides a reserve of iron, which can be transported for the synthesis of molecules such as cytochromes, haemoglobin and iron-sulphur compounds.
- Safe-guards cells, DNA, lipids and proteins from the potential toxic effects of iron.
Ferritin is a vital component of iron homeostasis. It acts as as a ferroxidase, converting Fe(II) to Fe(III) as iron is internalised and sequestered in the ferritin mineral core. Iron is toxic in cellular systems due to its capacity to generate reactive oxygen species (ROS) which directly damages cells, DNA, lipids and proteins 1.
Iron deficiency without anaemia is a diagnostic challenge, as it commonly goes unrecognised for a long period of time as the patient is asymptomatic. Ferritin is the most sensitive and specific test used in the diagnosis of iron deficiency, especially when a patient presents with symptoms of iron deficiency anaemia, but their full blood count is normal 2.
Adult onset Still’s Disease (AOSD) is a rare systemic inflammatory disorder characterised by arthritis, fever and a typical skin rash. Elevated ferritin levels have been observed in 89% of patients with AOSD, with five times the normal level observed in over half of patients 3.
Elevated ferritin levels is associated with a poor outcome in patients with sepsis and can be used as a predictive marker of mortality along with current prognostic scores 4. Elevations of both ferritin and CRP during hospitalisation was associated with the highest mortality, followed by elevations of either biomarker alone (fig. 1) 5.
Fig. 1. Risk contingency table for mortality and organ dysfunction based on cut-points for C-reactive protein and ferritin and patients’ maximum value for each biomarker 5
Data is displayed as n / N (%) for mortality outcomes
*Significant difference in high/intermediate versus low risk quadrants; {<0.001 by Mann-Whitney test PELOD2, Pediatric Logistic Organ Dysfunction Score 2
Ferritin is the most important acute phase reactant in the prediction of classical Hodgkin lymphoma (cHL). Ferritin correlates with the inflammatory activity of the cHL microenvironment, which could explain its prognostic impact. Elevated ferritin levels are associated with clinical features of aggressive disease and poor prognosis in cHL patients 6.
As an acute phase reactant, ferritin levels increase during inflammation and infection. Several studies have indicated that elevated ferritins levels were confirmed in the majority of hospitalised patients with COVID-19, approximately 60%. In the critically ill COVID-19 patients, extremely elevated ferritin concentrations were recorded, which could be attributed to a cytokine storm and secondary haemophagocytic lymphohistiocytosis (a hyperinflammatory syndrome associated with multiorgan failure) 7.
Specific Protein Calibrator
Specific Protein Control
Specific Protein EQA
References
Randox Sepsis innovation hailed by Health Secretary Matt Hancock
An innovative new tool for quickly diagnosing the often deadly infection Sepsis, will save lives, the Health Secretary has said.
The bedside test, being developed by healthcare diagnostics company Randox, will slash the 24 hours usually taken to identify the correct antibiotic for sepsis treatment. Currently, more than a third of those with sepsis die. Every hour that patients are not diagnosed increases the chance of death by 8%.
Health Secretary Matt Hancock said: “Instead of having to give people huge amounts of antibiotics across the board, which causes other problems, both medical and problems with resistance and super bugs, instead we will be able to work out exactly what the right treatment is for that individual person and do it fast enough to get the treatment in to save lives.”
He paid a visit to Randox’s new headquarters, the Randox Science Park, in Antrim, Northern Ireland on Thursday 21st March.
He added: “I can see a very clear application across the health service for how we can use the technology that is being developed here in Northern Ireland, both across the UK and indeed around the world.”
Sepsis can develop from infections caused by a simple cut or minor medical procedure. The body’s white blood cells fight the infection but the reaction can escalate and also damage healthy tissue.
Many who survive face amputations because of this tissue damage, Randox’s Molecular Diagnostics Manager Dr Martin Crockard said.
Dr Crockard highlighted that the traditional sepsis testing method, which involves sending blood samples to laboratories, takes too long. The problem is worsened by the fact that doctors are then forced to initially prescribe broad spectrum antibiotics which are not specific enough for individual patients. This encourages resistant strains.
To speed up the process, the new technology from Randox’s Biosciences division will allow clinicians in hospital emergency departments to check multiple samples simultaneously, at the press of a few buttons on a smart pad.
Dr Crockard said it is imperative that appropriate antibiotic treatment is administered as quickly as possible.
He said: “We can deal with the exact organism causing the problem in less than four hours, allowing you to tailor the treatment for that individual patient very quickly.”
The UK Sepsis Trust’s Chief Executive Ron Daniels said: “Randox is leading the way around molecular technologies.
“No other system brings this so close to the clinician on the shop floor.”
For further information please contact the Randox PR team by emailing randoxpr@randox.com or phoning 028 9442 2413
